Login to Your Account



Clinic Roundup


Monday, June 13, 2011
Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported final results from its pivotal Phase III STRIVE study showing that cystic fibrosis (CF) patients treated with VX-770 showed rapid improvements in lung function that were sustained through 48 weeks compared to placebo. Results showed a mean absolute improvement in lung function of 10.6 percent through week 24 and 10.5 percent through week 48.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription